

**FOUNDATION FOR ANGELMAN SYNDROME THERAPEUTICS,
TRANSFORMATX BIOTHERAPEUTICS LLC, MAVRIX BIO LLC, and
AS2 BIO INC**

**CONSOLIDATED FINANCIAL STATEMENTS AND INDEPENDENT
AUDITORS' REPORT**

YEARS ENDED DECEMBER 31, 2024 AND 2023

**FOUNDATION FOR ANGELMAN SYNDROME THERAPEUTICS,
TRANSFORMATX BIOTHERAPEUTICS LLC, MAVRIX BIO LLC, and AS2 BIO
INC
TABLE OF CONTENTS**

	<u>Pages</u>
INDEPENDENT AUDITOR’S REPORT	1 – 3
CONSOLIDATED STATEMENTS OF FINANCIAL POSITION	4 - 5
CONSOLIDATED STATEMENTS OF ACTIVITIES AND CHANGES IN NET ASSETS, MEMBERS’ EQUITY, AND STOCKHOLDERS’ EQUITY	6 - 7
CONSOLIDATED STATEMENTS OF FUNCTIONAL EXPENSES	8 – 9
CONSOLIDATED STATEMENTS OF CASH FLOWS	10 - 11
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS	12– 27
SUPPLEMENTARY INFORMATION:	
CONSOLIDATING STATEMENTS OF FINANCIAL POSITION	28 - 29
CONSOLIDATING STATEMENTS OF ACTIVITIES AND CHANGES IN NET ASSETS, MEMBERS’ EQUITY, AND STOCKHOLDERS’ EQUITY	30 - 31
CONSOLIDATING STATEMENTS OF FUNCTIONAL EXPENSES	32 - 33

INDEPENDENT AUDITOR'S REPORT

To the Officers and Directors
Foundation for Angelman Syndrome Therapeutics, TransformaTx Biotherapeutics LLC, MavriX Bio LLC, and AS2 Bio Inc
Marble Falls, TX

Report on the Audit of the Consolidated Financial Statements

Opinion

We have audited the accompanying consolidated financial statements of the Foundation for Angelman Syndrome Therapeutics (a nonprofit organization), TransformaTx Biotherapeutics LLC, MavriX Bio LLC, and AS2 Bio Inc (collectively the Organizations) which comprise the consolidated statements of financial position as of December 31, 2024, and the related consolidated statements of activities and changes in net assets, members' equity and stockholders' equity, functional expenses, and cash flows for the year then ended and the related notes to the consolidated financial statements.

In our opinion, the consolidated financial statements referred to above present fairly, in all material aspects, the financial position of the Organizations as of December 31, 2024, and the changes in its net assets, members' equity, and stockholders' equity and its cash flows for the year then ended in accordance with accounting principles generally accepted in the United States of America.

Basis for Opinion

We conducted our audit in accordance with audited standards generally accepted in the United States of America (GAAS). Our responsibilities under those standards are further described in the Auditor's Responsibilities for the Audit of the Consolidated Financial Statements section of our report. We are required to be independent of the Organizations and to meet our other ethical responsibilities, in accordance with the relevant ethical requirements relating to our audits. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our audit opinion.

Responsibilities of Management for the Consolidated Financial Statements

Management is responsible for the preparation and fair presentation of these consolidated financial statements in accordance with accounting principles generally accepted in the United States of America, and for the design, implementation, and maintenance of internal control relevant to the

preparation and fair presentation of consolidated financial statements that are free from material misstatement, whether due to fraud or error.

In preparing the consolidated financial statements, management is required to evaluate whether there are conditions or events, considered in the aggregate, that raise substantial doubt about the ability of the Organizations to continue as a going concern within one year after the date that the financial statements are available to be issued.

Auditor's Responsibilities for the Audit of the Consolidated Financial Statements

Our objectives are to obtain reasonable assurance about whether the consolidated financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance but not absolute assurance and therefore is not a guarantee that an audit conducted in accordance with generally accepted auditing standards will always detect a material misstatement when it exists. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control. Misstatements are considered material if there is a substantial likelihood that, individually or in the aggregate, they would influence the judgement made by a reasonable user based on the consolidated financial statements.

In performing an audit in accordance with generally accepted accounting standards, we:

- Exercise professional judgment and maintain professional skepticism throughout the audit.
- Identify and assess the risks of material misstatement of the consolidated financial statements, whether due to fraud or error, and design and perform audit procedures responsive to those risks. Such procedures include examining, on a test basis, evidence regarding the amounts and disclosures in the financial statements.
- Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the Organizations' internal control. Accordingly, no such opinion is expressed.
- Evaluate the appropriateness of accounting policies used and the reasonableness of significant accounting estimates made by management, as well as evaluate the overall presentation of financial statements.
- Conclude whether, in our judgment, there are conditions or events, considered in the aggregate, that raise substantial doubt about the Organizations' ability to continue as a going concern for a reasonable period of time.

We are required to communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit, significant audit findings, and certain internal control-related matters that we identified during the audit.

Report on Supplementary Information

Our audit was conducted for the purposes of forming an opinion on the consolidated financial statements as a whole. The supplementary information on pages 28-33 are presented for purposes of additional analysis and are not a required part of the financial statements. Such information is the responsibility of management and was derived from and relates directly to the underlying accounting and other records used to prepare the consolidated financial statements. The information has been subjected to the auditing procedures applied in the audit of the consolidated financial statements and certain additional procedures, including comparing and reconciling such information directly to the underlying accounting and other records used to prepare the financial statements or the consolidated financial statements themselves, and other additional procedures in accordance with auditing standards generally accepted in the United States of America. In our opinion, the information is fairly stated in all material respects in relation to the consolidated financial statements as a whole.

Hegre, McMahon & Schimmel, LLC

Oak Brook, Illinois
September 24, 2025

**FOUNDATION OF ANGELMAN SYNDROME THERAPEUTICS, TRANSFORMATX
BIOTHERAPEUTICS LLC, MAVRIX BIO LLC, and AS2 BIO INC
CONSOLIDATED STATEMENTS OF FINANCIAL POSITION
DECEMBER 31, 2024 AND 2023 (RESTATED)**

		RESTATED
	2024	2023
ASSETS		
Current Assets:		
Cash and cash equivalents	\$ 1,898,436	\$ 48,902,545
Contributions receivable, net of allowance for uncollectible pledges receivable of \$1,650,000 and \$2,000,000 for 2024 and 2023, respectively	415,000	219,320
Accounts receivable	661,380	-
Contract assets	22,800	-
Prepaid expenses	91,562	-
Investments at fair value	24,642,403	591
Investments at net asset value	6,281,350	5,674,102
	<u>34,012,931</u>	<u>54,796,558</u>
Property and Equipment:		
Website development	43,753	43,753
Less: Accumulated depreciation	<u>(43,753)</u>	<u>(43,753)</u>
Total property and equipment	<u>-</u>	<u>-</u>
Noncurrent assets:		
Right-of-use asset	47,521	68,626
Patents	351,009	305,153
Licenses, net accumulated amortization of \$10,048 and \$6,603 for 2024 and 2023	41,628	45,073
Investment in Couragene Inc. at cost	1,000,000	-
Investment in CourageAS, joint venture (equity method)	5,000,081	-
Total noncurrent assets	<u>6,440,239</u>	<u>418,852</u>
TOTAL ASSETS	<u><u>\$ 40,453,170</u></u>	<u><u>\$ 55,215,410</u></u>

The accompanying notes are an integral part of these consolidated financial statements.

**FOUNDATION OF ANGELMAN SYNDROME THERAPEUTICS, TRANSFORMATX
BIOTHERAPEUTICS LLC, MAVRIX BIO LLC, and AS2 BIO INC
CONSOLIDATED STATEMENTS OF FINANCIAL POSITION
DECEMBER 31, 2024 AND 2023 (RESTATED)**

		RESTATED
	2024	2023
LIABILITIES, NET ASSETS, MEMBERS' EQUITY, STOCKHOLDERS' EQUITY AND NONCONTROLLING INTERESTS		
Current Liabilities:		
Current portion of operating lease liabilities	\$ 22,801	\$ 22,734
Accounts payable and accrued expenses	975,917	937,005
Accrued bonus	205,000	19,554
Grants payable, net of discounted rate to present value of \$157,421 and \$275,661 for 2024 and 2023, respectively	1,710,787	8,753,898
Total current liabilities	2,914,505	9,733,191
Long-Term Liabilities:		
Operating lease liabilities	21,925	43,097
Grants payable, net of discounted rate to present value of \$737,637 and \$1,024,447 for 2024 and 2023, respectively	2,222,063	3,430,247
Total long-term liabilities	2,243,988	3,473,344
TOTAL LIABILITIES	5,158,493	13,206,535
Net assets:		
Without donor restrictions	40,192,607	43,836,909
With donor restrictions	15,457	15,457
TOTAL NET ASSETS	40,208,064	43,852,366
Members' equity	(4,436,185)	(1,707,626)
Noncontrolling interest	(390,419)	(135,865)
TOTAL MEMBERS' EQUITY AND NONCONTROLLING INTERESTS	(4,826,604)	(1,843,491)
Stockholders' equity:		
Common stock, \$.0001 par value 900,006 shares authorized, issued, and outstanding	93	-
Preferred stock, \$.0001 par value, 1,470,014 shares authorized, issued, and outstanding	147	-
Additional paid in capital (deficit)	(13,341)	-
Retained earnings (deficit)	(45,683)	-
Noncontrolling interest	(27,999)	-
TOTAL STOCKHOLDERS' EQUITY AND NONCONTROLLING INTEREST	(86,783)	-
TOTAL NET ASSETS, MEMBERS' EQUITY AND STOCKHOLDERS' EQUITY AND NONCONTROLLING INTERESTS	35,294,677	42,008,875
TOTAL LIABILITIES, NET ASSETS, MEMBERS' EQUITY STOCKHOLDERS' EQUITY AND NONCONTROLLING INTERESTS	\$ 40,453,170	\$ 55,215,410

The accompanying notes are an integral part of these consolidated financial statements.

**FOUNDATION OF ANGELMAN SYNDROME THERAPEUTICS, TRANSFORMATX
BIO THERAPEUTICS LLC, MAVRIX BIO LLC, and AS2 BIO INC
CONSOLIDATED STATEMENTS OF ACTIVITIES AND CHANGES IN NET ASSETS
MEMBERS' EQUITY AND STOCKHOLDERS' EQUITY
FOR THE YEAR ENDED DECEMBER 31, 2024**

	Without Donor Restrictions	With Donor Restrictions	Total
SUPPORT AND REVENUE			
General contributions	\$ 3,291,368	\$ -	\$ 3,291,368
Services	384,600	-	384,600
Special event revenues	322,583	-	322,583
Community fundraisers	432,376	-	432,376
Miscellaneous	39,540	-	39,540
Dividends and interest, net of investment advisory fees of \$71,481	1,403,453	-	1,403,453
Realized gains on investments	202,160	-	202,160
Unrealized gains on investments	752,159	-	752,159
Unrealized gains on level II investment	607,248	-	607,248
Net assets released from restrictions	-	-	-
Total support and revenue	7,435,487	-	7,435,487
EXPENSES			
Program expenses	12,672,953	-	12,672,953
Supporting Services			
Management and general	690,326	-	690,326
Fundraising	773,306	-	773,306
Total supporting services	1,463,632	-	1,463,632
Total expenses	14,136,585	-	14,136,585
Change in net assets	(6,701,098)	-	(6,701,098)
Less: Net income (loss) attributable to noncontrolling interest	(418,628)	-	(418,628)
Net loss attributable to FAST	(6,282,470)	-	(6,282,470)
NET ASSETS, MEMBERS' EQUITY AND STOCKHOLDERS' EQUITY, BEGINNING OF YEAR	41,993,418	15,457	42,008,875
Conversion of LLC shares into shares of common stock	93	-	93
Conversion of convertible note into preferred stock - par value	147	-	147
Contribution of LLC shares to AS2 Bio Inc. at deficit	(13,341)	-	(13,341)
NET ASSETS, MEMBERS' EQUITY AND STOCKHOLDERS' EQUITY, END OF YEAR	<u>\$ 35,279,219</u>	<u>\$ 15,457</u>	<u>\$ 35,294,677</u>

The accompanying notes are an integral part of these consolidated financial statements.

**FOUNDATION OF ANGELMAN SYNDROME THERAPEUTICS AND TRANSFORMATX
BIOTHERAPEUTICS LLC**
CONSOLIDATED STATEMENTS OF ACTIVITIES AND CHANGES IN NET ASSETS
MEMBERS' EQUITY AND STOCKHOLDERS' EQUITY
FOR THE YEAR ENDED DECEMBER 31, 2023 (RESTATED)

	RESTATED Without Donor Restrictions	With Donor Restrictions	Total
SUPPORT AND REVENUE			
General contributions, net of allowance for uncollectible pledges of \$2,000,000	\$ 1,097,676	\$ -	\$ 1,097,676
Special event revenues	218,275	-	218,275
Community fundraisers	768,600	-	768,600
Miscellaneous	16,232	-	16,232
Dividends and interest, net of investment advisory fees of \$37,037	1,932,276	-	1,932,276
Realized losses on derivative contracts	(350,522)	-	(350,522)
Realized gains on investments	2,696	-	2,696
Unrealized gains on investments	534,458	-	534,458
Unrealized gains on level II investment	174,102	-	174,102
Net assets released from restrictions	-	-	-
Total support and revenue	4,393,793	-	4,393,793
EXPENSES			
Program expenses	17,158,909	-	17,158,909
Supporting Services:			
Management and general	936,478	-	936,478
Fundraising	516,457	-	516,457
Total supporting services	1,452,935	-	1,452,935
Total expenses	18,611,844	-	18,611,844
Change in net assets from operations	(14,218,051)	-	(14,218,051)
Nonoperating activities			
Royalty payments - GeneTx	1,113,223	-	1,113,223
Change in net assets	(13,104,828)	-	(13,104,828)
NET ASSETS , beginning of year	55,098,246	15,457	55,113,703
NET ASSETS AND MEMBERS' EQUITY , end of year	\$ 41,993,418	\$ 15,457	\$ 42,008,875

The accompanying notes are an integral part of these consolidated financial statements.

**FOUNDATION OF ANGELMAN SYNDROME THERAPEUTICS, TRANSFORMATX
BIOTHERAPEUTICS LLC, MAVRIX BIO LLC, and AS2 BIO INC
CONSOLIDATED STATEMENT OF FUNCTIONAL EXPENSES
FOR THE YEAR ENDED DECEMBER 31, 2024**

		Supporting Services						
		Program Services	Management and General	Fundraising		Total Expenses		
EXPENSES								
Salaries and payroll taxes	\$	4,055,909	\$	473,094	\$	223,266	\$	4,752,269
Employee benefits		206,124		22,480		10,609		239,213
Payroll processing fees		37,288		4,507		2,127		43,922
Direct benefits to donors		1,498,804		-		374,701		1,873,505
Professional fees		1,116,107		45,824		-		1,161,931
Advertising and marketing		2,412		-		-		2,412
Public relations/consulting fees		695,531		21,272		10,039		726,842
Travel scholarships		54,431		-		-		54,431
Education and awareness		187,558		-		-		187,558
Research funding		3,698,573		-		-		3,698,573
Research and development costs		2,572,182		-		-		2,572,182
Board fees		33,329		-		-		33,329
Travel		141,926		16,850		16,850		175,626
Conferences and memberships		368,348		-		-		368,348
Computer and software		270,037		33,652		15,881		319,570
Office supplies		50,166		5,894		2,782		58,842
Insurance		37,829		13,047		13,047		63,923
Occupancy		2,362		-		-		2,362
Dues and subscriptions		9,063		-		-		9,063
Licenses and permits		10,218		8,829		-		19,047
Bank and merchant account fees		45,526		43,459		187		89,172
Printing and postage		6,412		-		-		6,412
Telephone		9,372		1,418		669		11,459
CAN expenses		168,154		-		84,077		252,231
Local fundraising expenses		19,071		-		19,071		38,142
Educational resources		32,800		-		-		32,800
Management fees		27,388		-		-		27,388
Amortization of licenses		3,445		-		-		3,445
Other		3,270		-		-		3,270
TOTAL EXPENSES	\$	15,363,635	\$	690,326	\$	773,306	\$	16,827,267

The accompanying notes are an integral part of these consolidated financial statements.

**FOUNDATION FOR ANGELMAN SYNDROME THERAPEUTICS AND TRANSFORMATX
BIOTHERAPEUTICS LLC**
CONSOLIDATED STATEMENT OF FUNCTIONAL EXPENSES - RESTATED
FOR THE YEAR ENDED DECEMBER 31, 2023

	RESTATED	Supporting Services		Total Expenses
	Program Services	Management and General	Fundraising	
EXPENSES				
Salaries and payroll taxes	\$ 917,883	\$ 326,428	\$ 148,335	\$ 1,392,646
Payroll processing fees	10,920	4,100	1,779	16,799
Direct benefits to donors	929,033	-	309,678	1,238,711
Professional fees	1,340,585	337,856	-	1,678,441
Video and production	24,960	-	-	24,960
Advertising and marketing	19,730	-	-	19,730
Travel scholarships	18,995	-	-	18,995
Education and awareness	428,418	-	-	428,418
Research funding	12,659,656	-	-	12,659,656
Research and development costs	706,503	-	-	706,503
Travel	20,683	32,288	-	52,971
Computer and software	2,245	140,829	-	143,074
Office supplies	1,497	21,620	-	23,117
Insurance	-	17,312	-	17,312
Interest	339	-	-	339
Licenses and permits	300	4,247	-	4,547
Bank and merchant account fees	-	41,768	-	41,768
Printing and postage	-	3,349	-	3,349
Telephone	-	5,435	-	5,435
CAN expenses	31,907	-	31,907	63,814
Local fundraising expenses	24,758	-	24,758	49,516
Depreciation	14,584	-	-	14,584
Amortization of licenses	3,445	-	-	3,445
Other	2,468	1,246	-	3,714
TOTAL EXPENSES	\$ 17,158,909	\$ 936,478	\$ 516,457	\$ 18,611,844

The accompanying notes are an integral part of these consolidated financial statements.

**FOUNDATION OF ANGELMAN SYNDROME THERAPEUTICS, TRANSFORMATX
BIOTHERAPEUTICS LLC, MAVRIX BIO LLC, and AS2 BIO INC
CONSOLIDATED STATEMENTS OF CASH FLOWS
FOR THE YEARS ENDED DECEMBER 31, 2024 and 2023 (RESTATED)**

	RESTATED	
	2024	2023
CASH FLOWS FROM OPERATING ACTIVITIES		
Change in net assets	\$ (6,701,098)	\$ (13,104,828)
Adjustments to reconcile change in net assets to net cash provided by (used in) operating activities		
Depreciation and amortization	3,445	18,029
Amortization expenses - right to use assets	21,105	17,930
Uncollectible pledge write off	-	-
Change in allowance for uncollectible pledges	(350,000)	2,000,000
Change in allowance for grants payable estimated to be unpaid	-	(6,031,508)
Discount on contributions receivable	(93,205)	-
Realized losses on derivative contracts	-	350,522
Unrealized gains on derivative contracts	-	-
Net realized and unrealized gains on investments	(954,319)	(537,154)
Unrealized gains on investment in Level II investment	(607,248)	(174,102)
 Increase in assets:		
Contributions receivable	247,525	97,565
Accounts receivable	(661,380)	237,886
Unbilled revenue	(22,800)	-
Prepaid expenses	(91,562)	-
Increase (decrease) in liabilities		
Accounts payable and accrued expenses	38,912	694,887
Accrued bonuses	185,446	-
Due to related party	-	(632,715)
Grants payable	(2,219,787)	11,182,446
Payments for operating lease liabilities	(21,105)	(20,727)
 Net cash provided by (used in) operating activities	<u>(11,226,071)</u>	<u>(5,901,769)</u>
 CASH FLOWS FROM INVESTING ACTIVITIES		
Receivables for pending investment transactions	-	19,595
Purchase of 640,000 preferred shares of Couragene, Inc. for 3.86% equity interest	(1,000,000)	-
Purchase of 23.94% of preferred stock and 14.36% of common stock of CourageAS a joint venture	(5,000,081)	-
Proceeds from sale of derivative contracts	-	6,475,557
Purchases of derivative contracts	-	(1,515,983)

The accompanying notes are an integral part of these consolidated financial statements.

**FOUNDATION OF ANGELMAN SYNDROME THERAPEUTICS, TRANSFORMATX
BIOTHERAPEUTICS LLC, MAVRIX BIO LLC, and AS2 BIO INC
CONSOLIDATED STATEMENTS OF CASH FLOWS
FOR THE YEARS ENDED DECEMBER 31, 2024 and 2023 (RESTATED)**

CASH FLOWS FROM INVESTING ACTIVITIES (Continued)

Purchases of level II investments	-	(5,500,000)
Proceeds from sale of stock investments	4,952,589	2,696
Purchases of stock investments	(34,684,690)	-
Reduction of note receivable for services provided	-	833,291
Legal costs associated with patents pending	<u>(45,856)</u>	<u>(63,139)</u>
Net cash provided by (used in) investing activities	<u>(35,778,038)</u>	<u>252,017</u>
CHANGE IN CASH AND CASH EQUIVALENTS	(47,004,109)	(5,649,752)
Cash and cash equivalents, beginning of year	<u>48,902,545</u>	<u>54,552,297</u>
CASH AND CASH EQUIVALENTS, END OF YEAR	<u>\$ 1,898,436</u>	<u>\$ 48,902,545</u>

SUPPLEMENTAL DISCLOSURE OF NON-CASH INVESTING ACTIVITIES

Reduction of convertible note receivable for services provided	<u>\$ -</u>	<u>\$ 833,291</u>
--	-------------	-------------------

SUPPLEMENTAL DISCLOSURE OF NON-CASH OPERATING ACTIVITIES

Right-of-use assets obtained in exchange for operating lease obligations	<u>\$ -</u>	<u>\$ 86,556</u>
--	-------------	------------------

The accompanying notes are an integral part of these consolidated financial statements.

SUPPLEMENTARY INFORMATION

**FOUNDATION OF ANGELMAN SYNDROME THERAPEUTICS, TRANSFORMATX BIOTHERAPEUTICS LLC,
MAVRIX BIO LLC, and AS2 BIO INC
CONSOLIDATING STATEMENT OF FINANCIAL POSITION
DECEMBER 31, 2024**

	FAST	TRANSFORMATX	MAVRIX	AS2	ELIMINATIONS	Total
ASSETS						
CURRENT ASSETS						
Cash and cash equivalents	\$ 1,155,343	\$ 85,143	\$ 35,092	\$ 622,858	\$ -	\$ 1,898,436
Contributions receivable, net of allowance for uncollectible pledges receivable of \$1,650,000	415,000	-	-	-	-	415,000
Accounts receivable	619,294	-	-	42,086	-	661,380
Due from related party	150,477	-	-	181,288	(331,765)	-
Contract assets	-	-	-	22,800	-	22,800
Prepaid expenses	26,029	2,600	-	62,933	-	91,562
Investments at fair value	24,642,403	-	-	-	-	24,642,403
Investments at net asset value	6,281,350	-	-	-	-	6,281,350
Total current assets	33,289,896	87,743	35,092	931,965	(331,765)	34,012,931
Property and Equipment:						
Website development	43,753	-	-	-	-	43,753
Less: Accumulated depreciation	(43,753)	-	-	-	-	(43,753)
Total property and equipment	-	-	-	-	-	-
Noncurrent Assets:						
Right-of-use asset	47,521	-	-	-	-	47,521
Patents	-	351,009	-	-	-	351,009
Licenses, net accumulated amortization of \$10,048	-	41,628	-	-	-	41,628
Investment in Courage Inc. at cost	1,000,000	-	-	-	-	1,000,000
Investment in CourageAS, joint venture (equity method)	5,000,081	-	-	-	-	5,000,081
Investment in TransformaTx Biotherapeutics LLC	3,195,274	-	-	-	(3,195,274)	-
Investment in MavriX Bio LLC	2,000,000	-	-	-	(2,000,000)	-
Investment in AS2 Bio Inc.	383,109	-	-	-	(383,109)	-
Total noncurrent assets	11,625,985	392,637	-	-	(5,578,383)	6,440,239
TOTAL ASSETS	\$44,915,881	\$ 480,380	\$ 35,092	\$ 931,965	\$ (5,910,148)	\$40,453,170
LIABILITIES, NET ASSETS, MEMBERS' EQUITY, STOCKHOLDERS' EQUITY AND NONCONTROLLING INTERESTS						
Current Liabilities:						
Current portion of operating lease liabilities	\$ 22,801	\$ -	\$ -	\$ -	\$ -	\$ 22,801
Accounts payable and accrued expenses	626,050	10,745	8,960	330,162	-	975,917
Accrued bonus	50,000	-	-	155,000	-	205,000
Due to related party	54,191	10,688	116,409	150,477	(331,765)	-
Grants payable, net of discounted rate to present value of \$157,421	1,710,787	-	-	-	-	1,710,787
Total current liabilities	2,463,829	21,433	125,369	635,639	(331,765)	2,914,505
Long-Term Liabilities:						
Operating lease liabilities	21,925	-	-	-	-	21,925
Grants payable, net of discounted rate to present value of \$737,637	2,222,063	-	-	-	-	2,222,063
Total long-term liabilities	2,243,988	-	-	-	-	2,243,988
TOTAL LIABILITIES	4,707,817	21,433	125,369	635,639	(331,765)	5,158,493
Net Assets						
Without donor restrictions	40,192,607	-	-	-	-	40,192,607
With donor restrictions	15,457	-	-	-	-	15,457
TOTAL NET ASSETS	40,208,064	-	-	-	-	40,208,064
Members' equity:						
Member contributions	-	3,195,274	2,000,000	-	(5,195,274)	-
Members' equity	-	(2,736,327)	(2,090,277)	-	-	(4,826,604)
TOTAL MEMBERS' EQUITY AND NONCONTROLLING INTERESTS	-	458,947	(90,277)	-	(5,195,274)	(4,826,604)
Stockholders' equity:						
Common stock	-	-	-	93	-	93
Preferred stock	-	-	-	147	-	147
Additional paid in capital	-	-	-	369,768	(383,109)	(13,341)
Retained earnings (deficit)	-	-	-	(73,682)	-	(73,682)
TOTAL STOCKHOLDERS' EQUITY AND NONCONTROLLING INTERESTS	-	-	-	296,326	(383,109)	(86,783)
TOTAL LIABILITIES, NET ASSETS, MEMBERS' EQUITY STOCKHOLDERS' EQUITY AND NONCONTROLLING INTERESTS	\$44,915,881	\$ 480,380	\$ 35,092	\$ 931,965	\$ (5,910,148)	\$40,453,170

The accompanying notes are an integral part of these consolidated financial statements.

FOUNDATION OF ANGELMAN SYNDROME THERAPEUTICS AND TRANSFORMATX BIOTHERAPEUTICS LLC
CONSOLIDATING STATEMENT OF FINANCIAL POSITION - RESTATED
DECEMBER 31, 2023

	FAST - RESTATED	TRANSFORMATX	ELIMINATIONS	Total
ASSETS				
Current Assets:				
Cash and cash equivalents	\$ 48,223,283	\$ 679,262	\$ -	\$ 48,902,545
Contributions receivable, net of allowance for uncollectible pledges of \$2,000,000	219,320	-	-	219,320
Investments at fair value	591	-	-	591
Investments at net asset value	5,674,102	-	-	5,674,102
Total current assets	54,117,296	679,262	-	54,796,558
Property and Equipment:				
Website development	43,753	-	-	43,753
Less: Accumulated depreciation	(43,753)	-	-	(43,753)
Total property and equipment	-	-	-	-
Noncurrent Assets:				
Right-of use asset	68,626	-	-	68,626
Patents	-	305,153	-	305,153
Licenses, net accumulated amortization of \$6,603	-	45,073	-	45,073
Investment in TransformaTx Biotherapeutics LLC	2,244,319	-	(2,244,319)	-
Total noncurrent assets	2,312,945	350,226	(2,244,319)	418,852
TOTAL ASSETS	<u>\$ 56,430,241</u>	<u>\$ 1,029,488</u>	<u>\$ (2,244,319)</u>	<u>\$ 55,215,410</u>
LIABILITIES, NET ASSETS, MEMBERS' EQUITY, AND NONCONTROLLING INTERESTS				
Current Liabilities:				
Current portion of operating lease liabilities	\$ 22,734	\$ -	\$ -	\$ 22,734
Accounts payable	327,900	609,105	-	937,005
Due to related party	-	19,554	-	19,554
Grants payable, net of discounted rate to present value of \$275,661	8,753,898	-	-	8,753,898
Total current liabilities	9,104,532	628,659	-	9,733,191
Long-Term Liabilities:				
Operating lease liabilities	43,097	-	-	43,097
Grants payable, net of discounted rate to present value of \$1,024,447 and allowance for grants payable of \$6,318,270	3,430,247	-	-	3,430,247
Total long-term liabilities	3,473,344	-	-	3,473,344
TOTAL LIABILITIES	12,577,876	628,659	-	13,206,535
Net Assets				
Without donor restrictions	43,836,909	-	-	43,836,909
With donor restrictions	15,457	-	-	15,457
TOTAL NET ASSETS	43,852,366	-	-	43,852,366
Members' equity				
Member contributions	-	1,676,131	(1,676,131)	-
Members' equity	-	(1,275,303)	(568,188)	(1,843,491)
TOTAL MEMBERS' EQUITY	-	400,828	(2,244,319)	(1,843,491)
TOTAL NET ASSETS AND MEMBERS' EQUITY	43,852,366	400,829	(2,244,319)	42,008,875
TOTAL LIABILITIES AND NET ASSETS	<u>\$ 56,430,241</u>	<u>\$ 1,029,488</u>	<u>\$ (2,244,319)</u>	<u>\$ 55,215,410</u>

The accompanying notes are an integral part of these consolidated financial statements.

**FOUNDATION OF ANGELMAN SYNDROME THERAPEUTICS, TRANSFORMATX BIOTHERAPEUTICS LLC,
MAVRIX BIO LLC, and AS2 BIO INC**
CONSOLIDATING STATEMENTS OF ACTIVITIES AND CHANGES IN NET ASSETS, MEMBERS' EQUITY AND STOCKHOLDERS' EQUITY
FOR THE YEAR ENDED DECEMBER 31, 2024

	FAST			TRANSFORMATX	MAVRIX	AS2		CONSOLIDATED		
	Without Donor Restrictions	With Donor Restrictions	Total	Without Donor Restrictions	Without Donor Restrictions	Without Donor Restrictions	Eliminations	Without Donor Restrictions	With Donor Restrictions	Total
SUPPORT AND REVENUE										
General contributions	\$ 3,291,368	\$ -	\$ 3,291,368	\$ -	\$ -	\$ -	\$ -	\$ 3,291,368	\$ -	\$ 3,291,368
Services	-	-	-	-	-	2,308,010	(1,923,410)	384,600	-	384,600
Special event revenues	322,583	-	322,583	-	-	-	-	322,583	-	322,583
Community fundraisers	432,376	-	432,376	-	-	-	-	432,376	-	432,376
Miscellaneous	39,540	-	39,540	-	-	-	-	39,540	-	39,540
Dividends and interest, net of investment investment advisory fees of \$71,481	1,403,453	-	1,403,453	-	-	-	-	1,403,453	-	1,403,453
Realized gains on investments	202,160	-	202,160	-	-	-	-	202,160	-	202,160
Unrealized gains on investments	752,159	-	752,159	-	-	-	-	752,159	-	752,159
Unrealized gains on level II investment	607,248	-	607,248	-	-	-	-	607,248	-	607,248
Net assets released from restrictions	-	-	-	-	-	-	-	-	-	-
Total support and revenue	<u>7,050,887</u>	<u>-</u>	<u>7,050,887</u>	<u>-</u>	<u>-</u>	<u>2,308,010</u>	<u>(1,923,410)</u>	<u>7,435,487</u>	<u>-</u>	<u>7,435,487</u>
EXPENSES										
Program expenses	9,231,557	-	9,231,557	892,837	2,090,277	2,381,692	(1,923,410)	12,672,953	-	12,672,953
Management and general	690,326	-	690,326	-	-	-	-	690,326	-	690,326
Fundraising	<u>773,306</u>	<u>-</u>	<u>773,306</u>	<u>-</u>	<u>-</u>	<u>-</u>	<u>-</u>	<u>773,306</u>	<u>-</u>	<u>773,306</u>
Total expenses	<u>10,695,189</u>	<u>-</u>	<u>10,695,189</u>	<u>892,837</u>	<u>2,090,277</u>	<u>2,381,692</u>	<u>(1,923,410)</u>	<u>14,136,585</u>	<u>-</u>	<u>14,136,585</u>
Change in net assets	(3,644,302)	-	(3,644,302)	(892,837)	(2,090,277)	(73,682)	-	(6,701,098)	-	(6,701,098)
NET ASSETS, beginning of year	<u>43,836,909</u>	<u>15,457</u>	<u>43,852,366</u>	<u>(1,843,490)</u>	<u>-</u>	<u>-</u>	<u>-</u>	<u>44,237,737</u>	<u>15,457</u>	<u>44,253,194</u>
NET ASSETS, end of year	<u>\$ 40,192,607</u>	<u>\$ 15,457</u>	<u>\$ 40,208,064</u>	<u>\$ (2,736,327)</u>	<u>\$ (2,090,277)</u>	<u>\$ (73,682)</u>	<u>\$ -</u>	<u>\$ 37,536,639</u>	<u>\$ 15,457</u>	<u>\$ 37,552,096</u>

The accompanying notes are an integral part of these consolidated financial statements.

FOUNDATION OF ANGELMAN SYNDROME THERAPEUTICS AND TRANSFORMATX BIOTHERAPEUTICS LLC
CONSOLIDATING STATEMENTS OF ACTIVITIES AND CHANGES IN NET ASSETS - RESTATED
FOR THE YEAR ENDED DECEMBER 31, 2023

	FAST - RESTATED			TRANSFORMATX			CONSOLIDATED		
	Without Donor Restrictions	With Donor Restrictions	Total	Without Donor Restrictions	With Donor Restrictions	Total	Without Donor Restrictions	With Donor Restrictions	Total
SUPPORT AND REVENUE									
General contributions, net of allowance for uncollectible pledges of \$2,000,000	\$ 1,097,676	\$ -	\$ 1,097,676	\$ -	\$ -	\$ -	\$ 1,097,676	\$ -	\$ 1,097,676
Special event revenues	218,275	-	218,275	-	-	-	218,275	-	218,275
Community fundraisers	768,600	-	768,600	-	-	-	768,600	-	768,600
Miscellaneous	16,232	-	16,232	-	-	-	16,232	-	16,232
Dividends and interest, net of investment investment advisory fees of \$37,037	1,932,276	-	1,932,276	-	-	-	1,932,276	-	1,932,276
Realized losses on derivative contracts	(350,522)	-	(350,522)	-	-	-	(350,522)	-	(350,522)
Realized gains on investments	2,696	-	2,696	-	-	-	2,696	-	2,696
Unrealized gains on investments	534,458	-	534,458	-	-	-	534,458	-	534,458
Unrealized gains on level II investment	174,102	-	174,102	-	-	-	174,102	-	174,102
Net assets released from restrictions	-	-	-	-	-	-	-	-	-
Total support and revenue	<u>4,393,793</u>	<u>-</u>	<u>4,393,793</u>	<u>-</u>	<u>-</u>	<u>-</u>	<u>4,393,793</u>	<u>-</u>	<u>4,393,793</u>
EXPENSES									
Program expenses	16,017,356	-	16,017,356	1,141,553	-	1,141,553	17,158,909	-	17,158,909
Management and general	936,478	-	936,478	-	-	-	936,478	-	936,478
Fundraising	<u>516,457</u>	<u>-</u>	<u>516,457</u>	<u>-</u>	<u>-</u>	<u>-</u>	<u>516,457</u>	<u>-</u>	<u>516,457</u>
Total expenses	<u>17,470,291</u>	<u>-</u>	<u>17,470,291</u>	<u>1,141,553</u>	<u>-</u>	<u>1,141,553</u>	<u>18,611,844</u>	<u>-</u>	<u>18,611,844</u>
Change in net assets from operations	(13,076,498)	-	(13,076,498)	(1,141,553)	-	(1,141,553)	(14,218,051)	-	(14,218,051)
Nonoperating activities									
Royalty payments - Genetx	<u>1,113,223</u>	<u>-</u>	<u>1,113,223</u>	<u>-</u>	<u>-</u>	<u>-</u>	<u>1,113,223</u>	<u>-</u>	<u>1,113,223</u>
Change in net assets	<u>(11,963,275)</u>	<u>-</u>	<u>(11,963,275)</u>	<u>(1,141,553)</u>	<u>-</u>	<u>(1,141,553)</u>	<u>(13,104,828)</u>	<u>-</u>	<u>(13,104,828)</u>
NET ASSETS, beginning of year	55,800,184	15,457	55,815,641	(133,750)	-	(133,750)	55,666,434	15,457	55,681,891
Member contributions	<u>-</u>	<u>-</u>	<u>-</u>	<u>1,676,131</u>	<u>-</u>	<u>1,676,131</u>	<u>1,676,131</u>	<u>-</u>	<u>1,676,131</u>
NET ASSETS, end of year	<u>\$ 43,836,909</u>	<u>\$ 15,457</u>	<u>\$ 43,852,366</u>	<u>\$ 400,828</u>	<u>\$ -</u>	<u>\$ 400,828</u>	<u>\$ 44,237,737</u>	<u>\$ 15,457</u>	<u>\$ 44,253,194</u>

The accompanying notes are an integral part of these consolidated financial statements.

**FOUNDATION OF ANGELMAN SYNDROME THERAPEUTICS, TRANSFORMATX BIOTHERAPEUTICS LLC,
MAVRIX BIO LLC, and AS2 BIO INC
CONSOLIDATING STATEMENT OF FUNCTIONAL EXPENSES
FOR THE YEAR ENDED DECEMBER 31, 2024**

	FAST				FOR-PROFIT ENTITIES				CONSOLIDATED			
	Program Services	Management and General	Fundraising	Total	TRANSFORMATX	MAVRIX	AS2	Total	Total Program Services	Total Management and General	Total Fundraising	Total
Salaries and payroll taxes	\$ 2,097,630	\$ 473,094	\$ 223,266	\$ 2,793,990	\$ -	\$ -	\$ 1,958,279	\$ 1,958,279	\$ 4,055,909	\$ 473,094	\$ 223,266	\$ 4,752,269
Employee benefits	99,673	22,480	10,609	132,762	-	-	73,362	73,362	206,124	22,480	10,609	239,213
Payroll processing fees	19,981	4,507	2,127	26,615	-	-	10,673	10,673	37,288	4,507	2,127	43,922
Direct benefits to donors	1,124,103	-	374,701	1,498,804	-	-	-	-	1,498,804	-	374,701	1,873,505
Professional fees	752,775	45,824	-	798,599	77,025	28,841	211,642	317,508	1,116,107	45,824	-	1,161,931
Advertising and marketing	-	-	-	-	-	-	2,412	2,412	2,412	-	-	2,412
Public relations/consulting fees	371,180	21,272	10,039	402,491	166,805	96,235	30,000	293,040	695,531	21,272	10,039	726,842
Travel scholarships	54,431	-	-	54,431	-	-	-	-	54,431	-	-	54,431
Education and awareness	187,558	-	-	187,558	-	-	-	-	187,558	-	-	187,558
Research funding	3,698,573	-	-	3,698,573	-	-	-	-	3,698,573	-	-	3,698,573
Research and development costs	-	-	-	-	607,304	1,964,878	-	2,572,182	2,572,182	-	-	2,572,182
Board fees	-	-	-	-	-	-	33,329	33,329	33,329	-	-	33,329
Travel	92,380	16,850	16,850	126,080	109	-	15,737	15,846	141,926	16,850	16,850	175,626
Conferences and memberships	367,048	-	-	367,048	1,115	-	185	1,300	368,348	-	-	368,348
Computer and software	207,764	33,652	15,881	257,297	6,238	-	6,502	12,740	270,037	33,652	15,881	319,570
Office supplies	26,133	5,894	2,782	34,809	-	-	15,357	15,357	50,166	5,894	2,782	58,842
Insurance	-	13,047	13,047	26,094	1,300	-	10,435	11,735	37,829	13,047	13,047	63,923
Occupancy	-	-	-	-	1,518	148	696	2,362	2,362	-	-	2,362
Dues and subscriptions	-	-	-	-	-	-	9,063	9,063	9,063	-	-	9,063
Licenses and permits	-	8,829	-	8,829	500	145	744	1,389	10,218	8,829	-	19,047
Bank and merchant account fees	1,754	43,459	187	45,400	90	30	6	126	45,526	43,459	187	89,172
Printing and postage	6,412	-	-	6,412	-	-	-	-	6,412	-	-	6,412
Telephone	6,285	1,418	669	8,372	-	-	1,000	1,000	9,372	1,418	669	11,459
CAN expenses	84,077	-	84,077	168,154	-	-	-	-	168,154	-	84,077	252,231
Local fundraising expenses	-	-	19,071	19,071	-	-	-	-	19,071	-	19,071	38,142
Educational resources	32,800	-	-	32,800	-	-	-	-	32,800	-	-	32,800
Management fees	-	-	-	-	27,388	-	-	27,388	27,388	-	-	27,388
Amortization of licenses	-	-	-	-	3,445	-	-	3,445	3,445	-	-	3,445
Other	1,000	-	-	1,000	-	-	2,270	2,270	3,270	-	-	3,270
TOTAL EXPENSES	\$ 9,231,557	\$ 690,326	\$ 773,306	\$10,695,189	\$ 892,837	\$ 2,090,277	\$ 2,381,692	\$ 5,364,806	\$15,363,635	\$ 690,326	\$ 773,306	\$16,827,267

The accompanying notes are an integral part of these consolidated financial statements.

FOUNDATION OF ANGELMAN SYNDROME THERAPEUTICS AND TRANSFORMATX BIOTHERAPEUTICS LLC
CONSOLIDATING STATEMENT OF FUNCTIONAL EXPENSES - RESTATED
FOR THE YEAR ENDED DECEMBER 31, 2023

	FAST - RESTATED				TRANSFORMATX				CONSOLIDATED			
	Program Services	Management and General	Fundraising	Total	Program Services	Management and General	Fundraising	Total	Total Program Services	Total Management and General	Total Fundraising	Total
Salaries and payroll taxes	\$ 899,876	\$ 326,428	\$ 148,335	\$ 1,374,639	\$ 18,007	\$ -	\$ -	\$ 18,007	\$ 917,883	\$ 326,428	\$ 148,335	\$ 1,392,646
Payroll processing fees	10,920	4,100	1,779	16,799	-	-	-	-	10,920	4,100	1,779	16,799
Direct benefits to donors	929,033	-	309,678	1,238,711	-	-	-	-	929,033	-	309,678	1,238,711
Professional fees	932,312	337,856	-	1,270,168	408,273	-	-	408,273	1,340,585	337,856	-	1,678,441
Video and production	24,960	-	-	24,960	-	-	-	-	24,960	-	-	24,960
Advertising and marketing	19,730	-	-	19,730	-	-	-	-	19,730	-	-	19,730
Travel scholarships	18,995	-	-	18,995	-	-	-	-	18,995	-	-	18,995
Education and awareness	428,418	-	-	428,418	-	-	-	-	428,418	-	-	428,418
Research funding	12,659,656	-	-	12,659,656	-	-	-	-	12,659,656	-	-	12,659,656
Research and development costs	-	-	-	-	706,503	-	-	706,503	706,503	-	-	706,503
Travel	19,739	32,288	-	52,027	944	-	-	944	20,683	32,288	-	52,971
Computer and software	-	140,829	-	140,829	2,245	-	-	2,245	2,245	140,829	-	143,074
Office supplies	-	21,620	-	21,620	1,497	-	-	1,497	1,497	21,620	-	23,117
Insurance	-	17,312	-	17,312	-	-	-	-	-	17,312	-	17,312
Interest	-	-	-	-	339	-	-	339	339	-	-	339
Licenses and permits	-	4,247	-	4,247	300	-	-	300	300	4,247	-	4,547
Bank and merchant account fees	-	41,768	-	41,768	-	-	-	-	-	41,768	-	41,768
Printing and postage	-	3,349	-	3,349	-	-	-	-	-	3,349	-	3,349
Telephone	-	5,435	-	5,435	-	-	-	-	-	5,435	-	5,435
CAN expenses	31,907	-	31,907	63,814	-	-	-	-	31,907	-	31,907	63,814
Local fundraising expenses	24,758	-	24,758	49,516	-	-	-	-	24,758	-	24,758	49,516
Depreciation	14,584	-	-	14,584	-	-	-	-	14,584	-	-	14,584
Amortization of licenses	-	-	-	-	3,445	-	-	3,445	3,445	-	-	3,445
Other	2,468	1,246	-	3,714	-	-	-	-	2,468	1,246	-	3,714
TOTAL EXPENSES	\$ 16,017,356	\$ 936,478	\$ 516,457	\$ 17,470,291	\$ 1,141,553	\$ -	\$ -	\$ 1,141,553	\$ 17,158,909	\$ 936,478	\$ 516,457	\$ 18,611,844

The accompanying notes are an integral part of these consolidated financial statements.

**FOUNDATION FOR ANGELMAN SYNDROME THERAPEUTICS, TRANSFORMATX
BIOTHERAPEUTICS LLC, MAVRIX BIO LLC, and AS2 BIO INC
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
FOR THE YEARS ENDED DECEMBER 31, 2024 AND 2023**

1. NATURE OF ACTIVITIES

The Foundation for Angelman Syndrome Therapeutics (“FAST”) was incorporated under the laws of the state of California on August 19, 2008, as a not-for-profit corporation for educational and other purposes and is exempt from federal income tax under Section 501(c)(3) of the Internal Revenue Code. Over the years, the Foundation has endowed several medical grants and research programs targeted at finding treatments and a cure for the neurological disorder of Angelman Syndrome. Their main sources of revenue come from contributions from individuals, foundations, and corporations as well as from ticket sales and sponsorships for FAST’s annual gala.

FAST formed TransformaTx Biotherapeutics LLC (TransformaTx), a Delaware Limited Liability Company in November 2021. The biotechnology company is singularly focused on developing and commercializing a safe and effective therapy for the treatment of Angelman Syndrome. The Company is currently conducting research and development activities related to their focus area. The Company was launched as a for-profit entity of FAST, a patient non-profit advocacy organization and the largest non-governmental funder of Angelman Syndrome research.

FAST formed MavriX Bio, LLC (MavriX), a Delaware Limited Liability Company in November 2024. The biotechnology company is singularly focused on advancing the first AAV-delivered, investigational gene replacement therapy for Angelman syndrome representing a major step toward clinical translation for a disorder with no approved disease-modifying treatments. The Company is currently conducting research and development activities related to their focus area. The Company was launched as a for-profit entity of FAST, a patient non-profit advocacy organization and the largest non-governmental funder of Angelman Syndrome research.

FAST invested in AS2 Bio Inc, (AS2) a Delaware Corporation through converting a convertible note into equity in January 2024. AS2 is a therapeutic accelerator to support the development of multiple treatment strategies for Angelman syndrome. By fostering and managing biotech companies focused on gene therapy, gene editing, and other innovative approaches, AS2 is driving the rapid translation of scientific breakthroughs into clinic treatment.

Collectively, FAST and the related entities will be referred to as “the Organizations” throughout the notes to the consolidated financial statements.

2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

Principles of Consolidation and Presentation

The consolidated financial statements include accounts of FAST as well as three for-profit entities. All significant intercompany accounts and transactions have been eliminated in the consolidated financial statements.

**FOUNDATION FOR ANGELMAN SYNDROME THERAPEUTICS, TRANSFORMATX
BIOTHERAPEUTICS LLC, MAVRIX BIO LLC, and AS2 BIO INC
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
FOR THE YEARS ENDED DECEMBER 31, 2024 AND 2023**

2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Continued)

Principles of Consolidation and Presentation (Continued)

FAST has investments in all three entities and exerts common control in the form of having overlapping board members with voting rights and employees in each entity. FAST's ownership and investment through ownership of members' interest in the LLCs or preferred stock in AS2 as follows as of December 31, 2024 and 2023, respectively:

	2024		2023
Investments in:			
TransformaTx	\$ 3,195,274		\$ 2,244,319
MavriX	2,000,000		-
AS2	383,109		-
	<u>\$ 5,578,383</u>		<u>\$ 2,244,319</u>
	2024		2023
Members' interest in partnerships (LLC's)			
TransformaTx, member units 2,999,789	<u>92.63</u>	%	<u>92.63</u> %
MavriX, member units 2,900,000	<u>90.00</u>	%	<u>-</u> %
Stock ownership in AS2			
1,470,014 shares of preferred stock with par value of .0001	<u>62.00</u>	%	<u>-</u> %

Financial Statement Presentation

The consolidated financial statements of the Organizations' have been prepared in accordance with accounting principles generally accepted in the United States of America ("GAAP").

GAAP requires FAST to report information regarding its financial position and activities according to the following net asset classifications:

Net assets without donor restrictions: Net assets that are not subject to donor-imposed restrictions and may be expended for any purpose in performing the primary objectives of the organization. These net assets may be used at the discretion of FAST's management and the board of directors.

Net assets with donor restrictions: Net assets subject to stipulations imposed by donors and grantors. Some donor restrictions are temporary in nature; those restrictions will be met by actions of FAST or by the passage of time. Other donor restrictions are perpetual in nature, whereby the donor has stipulated the funds be maintained in perpetuity.

**FOUNDATION FOR ANGELMAN SYNDROME THERAPEUTICS, TRANSFORMATX
BIOTHERAPEUTICS LLC, MAVRIX BIO LLC, and AS2 BIO INC
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
FOR THE YEARS ENDED DECEMBER 31, 2024 AND 2023**

2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Continued)

Donor restricted contributions are reported as increases in net assets with donor restrictions. When a restriction expires, net assets are reclassified from net assets with donor restrictions to net assets without donor restrictions in the statements of activities. Contributions that are donor-restricted for which the restriction is satisfied in the same reporting period are classified as without donor restrictions.

FAST has no net assets with donor restrictions that are perpetual in nature.

Cash and Cash Equivalents

The Organizations' cash consists of cash on deposit with banks. Cash equivalents represent money market funds, US Treasuries or short-term investments with original maturities of three months or less from the date of purchase.

Concentrations of Credit Risk

Financial instruments that potentially subject the Organizations to concentrations of credit risk consist principally of cash and cash equivalents and investments. The Organizations maintain their cash and cash equivalents in various bank accounts that, at times, may exceed federally insured limits which have been placed with high credit quality financial institutions. The Organizations have not experienced, nor does it anticipate, any losses with respect to such accounts.

Contributions Receivable

Unconditional promises to give that are expected to be collected within one year are recorded at net realizable value. Unconditional promises to give that are expected to be collected in future years are recorded at the present value of their estimated future cash flows. The discounts on those amounts are computed using risk-adjusted interest rates applicable to the years in which the promises are received. Discount amortization, if any, is included in contribution revenue. For the years ended December 31, 2024 and 2023, there was no discount rate calculated as long-term pledges had an allowance for uncollectible pledges totaling \$1,650,000 and \$2,000,000 as of December 31, 2024 and 2023, respectively.

Accounts Receivable

FAST's accounts receivable consist of refunds on grants they had previously paid out totaling \$867,889 and reimbursement of legal costs as related to their investment in Couragene, Inc. totaling \$146,825 for the year ended December 31, 2024. FAST did not have any accounts receivable for the year ended December 31, 2024. FAST typically does not have accounts receivable related to normal operations of the Organization and receives income predominately through contributions, fundraising, and special events.

**FOUNDATION FOR ANGELMAN SYNDROME THERAPEUTICS, TRANSFORMATX
BIOTHERAPEUTICS LLC, MAVRIX BIO LLC, and AS2 BIO INC
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
FOR THE YEARS ENDED DECEMBER 31, 2024 AND 2023**

2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Continued)

Accounts Receivable (Continued)

AS2 provides services to related parties and unrelated third parties for management services. The carrying amount of accounts receivable is reduced by an allowance that reflects management's best estimate of current expected credit losses. The estimate of the allowance for credit losses is based on an analysis of historical loss experience, current receivables aging, and management's assessment of current conditions and expected changes during a reasonable and supportable forecast period. AS2 uses an aging method to estimate allowances for credit losses. Management assesses collectability by pooling receivables with similar risk characteristics and evaluates receivables individually when specific receivable balances no longer share those risk characteristics. Management has determined there is no allowance for credit losses necessary at December 31, 2024. There were no credit loss write offs for the year ended December 31, 2024.

Investments

Investments are reported at cost, if purchased, or at fair value, if donated. Thereafter, investments are reported at their fair value in the consolidated statements of financial position, and changes in fair value are reported as investment return in the consolidated statements of activities.

Purchases and sales of securities are reflected on a trade-date basis. Gains and losses on sales of securities are based on average cost and are recorded in the statements of activities in the period in which the securities are sold. Interest is recorded when earned. Dividends are accrued as of the ex-dividend date.

Fair Value of Financial Instruments

The carrying amount of cash and cash equivalents, contributions receivable, accounts receivable, accounts payable and accrued expenses, and accrued bonus approximate fair value due to the short maturity of these instruments.

Fair value is defined as the price that would be received to sell an asset in the principal or most advantageous market for the asset in an orderly transaction between market participants on the measurement date. Fair value should be based on the assumptions market participants would use when pricing an asset. GAAP establishes a fair value hierarchy that prioritizes investments based on those assumptions. The fair value hierarchy gives the highest priority to quoted prices in active markets (observable inputs) and the lowest priority to an entity's assumptions

**FOUNDATION FOR ANGELMAN SYNDROME THERAPEUTICS, TRANSFORMATX
BIOTHERAPEUTICS LLC, MAVRIX BIO LLC, and AS2 BIO INC
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
FOR THE YEARS ENDED DECEMBER 31, 2024 AND 2023**

2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Continued)

(unobservable inputs). FAST groups assets at fair value in three levels, based on the markets in which the assets and liabilities are traded, and the reliability of the assumptions used to determine fair value. These levels are:

- Level 1 - Unadjusted quoted market prices for identical assets or liabilities in active markets as of the measurement date.
- Level 2 - Other observable inputs, either directly or indirectly, including:
 - Quoted prices for similar assets / liabilities in active markets;
 - Quoted prices for identical or similar assets in non-active markets;
 - Inputs other than quoted prices that are observable for the asset / liability; and,
 - Inputs that are derived principally from or corroborated by other observable market data. The Foundation does not have any investments valued with level 2 inputs.
- Level 3 - Unobservable inputs that cannot be corroborated by observable market data. The Foundation does not have any investments valued with level 3 inputs.

Where quoted market prices are available in an active market, securities are classified within Level 1 of the valuation hierarchy. If quoted market prices are not available, then fair values are estimated by using pricing models, quoted prices of securities with similar characteristics or discounted cash flows and such investments are classified as Level 2. Level 2 investment valuations are based on quoted net asset value (NAV) of shares held at year-end.

Website Development Costs

It is FAST's policy to capitalize costs incurred in developing a new website over \$2,500. These costs are amortized over three years from the date the website was operational. The website was operational in 2021. All costs incurred in providing maintenance for the website are expensed as incurred. Depreciation expense was \$14,584 for the year ended December 31, 2023. The website was fully depreciated as of December 31, 2023; therefore, there is no depreciation expense for the year ended December 31, 2024.

Patents

TransformaTx incurred legal fees to apply for numerous patents during 2024 and 2023. For the years ended December 31, 2024 and 2023, the cumulative amount of legal fees capitalized as related to the patents totaled \$351,009 and \$305,153, respectively. The patents will be amortized on the date the patents are issued and approved until the date the patents expire. In 2024 and 2023, all patents were pending approval.

Licenses

TransformaTx acquired licenses in 2022 as related to their research. The amount of the license fees paid are \$51,676 and are amortized straight-line over a fifteen-year period. Amortization was \$3,445 for 2024 and 2023 respectively.

**FOUNDATION FOR ANGELMAN SYNDROME THERAPEUTICS, TRANSFORMATX
BIOTHERAPEUTICS LLC, MAVRIX BIO LLC, and AS2 BIO INC
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
FOR THE YEARS ENDED DECEMBER 31, 2024 AND 2023**

2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Continued)

Research and Development Costs

Research and development costs are expensed as incurred.

Contributions

Contributions received are recorded as net assets without donor restrictions or net assets with donor restrictions, depending on the existence and / or nature of any donor-imposed restrictions. Contributions that are restricted by the donor are reported as an increase in net assets without donor restrictions if the restriction expires in the reporting period in which the contribution is recognized. All other donor restricted contributions are reported as an increase in net assets with donor restrictions, depending on the nature of restriction. When a restriction expires (that is, when a stipulated time restriction ends or purpose restriction is accomplished), net assets with donor restrictions are reclassified to net assets without donor restrictions and reported in the statements of activities as net assets released from restrictions.

Special Event Revenues

Special event revenues consist of the fair market value of ticket sales for FAST's one gala in November as well as sponsorships related to the event. Special event revenues also consist of any income derived from the event such as silent auction funds and raffles.

The following revenue stream is included in the new revenue standard, Accounting Standards Update (ASU) No. 2014-09, Revenue from Contracts with Customers (Topic 606): Special event benefits (non-donation portion of ticket sales).

FAST records special event ticket sales at the time of admission. Tickets sold in advance are recorded as deferred revenue until performance obligations are met. All sales are non-refundable. Ticket sales are comprised of an exchange element based on the value of benefits provided, and a contribution element for the difference between the fair market value of the ticket and the total price paid. All performance obligations were met as of December 31, 2024 and 2023; thus, no deferred revenue is recorded.

Payment terms and rights are identifiable on each purchase order. Performance obligations are satisfied when access is given to the annual gala which requires access with a ticket. There are no significant financing components. There are no multiple performance obligations.

For all special events, the transaction price is the fair market value of the tickets. The excess of the fair market value of the tickets purchased and the actual price paid for the ticket is treated as a contribution and recognized as revenue on the date of ticket purchase.

Community Fundraisers

FAST and associated individuals raise money through special fundraising events. Contributions from these events are recorded as income upon receipt.

**FOUNDATION FOR ANGELMAN SYNDROME THERAPEUTICS, TRANSFORMATX
BIOTHERAPEUTICS LLC, MAVRIX BIO LLC, and AS2 BIO INC
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
FOR THE YEARS ENDED DECEMBER 31, 2024 AND 2023**

2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Continued)

Revenue Recognition

AS2 has management contracts with related and unrelated third parties to provide services on a monthly basis. AS2 performs the following five steps for contracts within the scope of FASB ASC 606: (1) identify the contracts with a customer; (2) identify the performance obligations in the contract; (3) determine the transaction price; (4) allocate the transaction price to the performance obligation in the contract; (5) recognize revenue when or as AS2 satisfies a performance obligation.

AS2 derives its revenue by providing management services for related and unrelated third parties, mostly consisting of employment services that are reimbursed based on hours of work pertaining to that customer. These services are delivered remotely. Revenue is recognized once the services for the month are completed and invoiced at a point in time. There are no prepayments for services to be rendered. Invoices are mostly sent monthly.

The transaction price is the invoiced amount provided. Payment terms on invoiced amounts are typically 30 days. A significant financing component does not exist.

All of AS2's performance obligations contain a single performance obligation that is satisfied at a point in time when the services have been provided and the invoice is sent. Revenue is recognized at a point in time because transfer of control to the customer for the work being performed does not occur until the work is completed for the month.

Contract assets are created from timing differences between customer invoicing and revenue recognition. From time to time, AS2 has work in progress that has not been billed in which services have been rendered. For the year ended December 31, 2024, contract assets for unbilled receivables were \$22,800. There were no contract liabilities for the year then ended.

Contributions of Goods and Services

Contributions of services are recognized at fair value when received if the services require specialized skills, are provided by individuals or entities possessing those skills, and would have typically needed to be purchased if not donated. Contributions of goods are recorded at fair value upon receipt when there is an objective and reasonable basis upon which to value the in-kind contributions. There were no contributions of goods or services for the year ended December 31, 2024 or 2023, respectively.

FAST has a global Cure Angelman Now online fundraising campaign initiative to raise funds to support FAST's mission to cure Angelman Syndrome. In 2024, FAST had 41 active CAN campaigns in the United States as well as their signature fundraiser, the annual FAST Gala. These events involve an estimated 291 volunteers to support the local fundraisers such as golf tournaments, private activity events, dinners, and other activities. These volunteers help our host families with registration, silent auctions, event turnout, and event execution. The estimated total hours for these efforts is 2,550.

**FOUNDATION FOR ANGELMAN SYNDROME THERAPEUTICS, TRANSFORMATX
BIOTHERAPEUTICS LLC, MAVRIX BIO LLC, and AS2 BIO INC
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
FOR THE YEARS ENDED DECEMBER 31, 2024 AND 2023**

2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Continued)

Donated marketable securities are recorded as stock donations in-kind at fair market value on the consolidated statements of activities and changes in net assets at their estimated fair value on the date of donation.

Functional Expenses

The costs of providing programs and other activities have been summarized on a functional basis in the consolidated statements of activities and on a detailed basis on the consolidated statement of functional expenses. Accordingly, certain costs have been allocated among programming and supporting services benefited based on estimates made by management. Costs associated with a specific program or supporting service have been charged directly to that program or supporting service. Costs that benefit more than one program or supporting service have been allocated among the programs and supporting services benefited based on an equitable basis. Payroll and payroll taxes have been allocated based on time and effort. All other costs have been directly charged.

Grants Payable

Grants authorized but unpaid at year end are reported as liabilities in accordance with SFAS No. 116, *Accounting for Contributions Received and Contributions Made*. Grants to be paid in more than one year are discounted using the long-term federal rate applicable at December 31, 2024 and 2023, respectively.

Use of Estimates

The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect certain reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities at the date of the financial statements, and the reported amounts of revenues and expenses during the reporting periods. Actual results could differ from those estimates.

Income Taxes

FAST is exempt from income tax under Internal Revenue Code (Code) section 501(c)(3), though it is subject to tax on income unrelated to its exempt purpose, unless that income is otherwise excluded by the Code. FAST has processes presently in place to ensure the maintenance of its tax-exempt status; to identify and report unrelated income; to determine its filing and tax obligations in jurisdictions for which it has nexus; and to identify and evaluate other matters that may be considered tax positions. FAST has determined that there are no material uncertain tax positions that require recognition or disclosure in the financial statements as of December 31, 2024 and 2023.

TransformaTx and MavriX have elected to be taxed as a partnership for federal and state income tax purposes, and accordingly, there is no provision for income taxes in the accompanying consolidated financial statements. The members of a partnership are taxed on their proportionate share of the Company's taxable income or receive the benefit of the Company's taxable losses based on allocations provided in the partnership agreement.

**FOUNDATION FOR ANGELMAN SYNDROME THERAPEUTICS, TRANSFORMATX
BIOTHERAPEUTICS LLC, MAVRIX BIO LLC, and AS2 BIO INC
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
FOR THE YEARS ENDED DECEMBER 31, 2024 AND 2023**

2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Continued)

AS2 has elected to be taxed as a C Corporation under the Internal Revenue Code. The Company does not currently have any federal or state tax liability nor is there any uncertainty regarding the use of any federal tax benefit from any losses reported as of December 31, 2024. Accordingly, no provision or liability for federal or state income taxes is reflected in the accompanying consolidated financial statements.

The Company does not have any material temporary differences between the timing of book and taxable income and expenses. Accordingly, there are no deferred tax assets or liabilities reflected in the accompanying consolidating financial statements.

Leases

FAST has a software services agreement with a third party to utilize software over a 5-year period which qualifies as a right-of-use asset and classified as an operating lease. Operating leases are included in operating lease right-of-use (ROU) assets, current portion of operating lease liabilities, and operating lease liabilities on the statements of financial position.

ROU assets represent the Organization's right to use an underlying asset for the lease term and lease liabilities represent the obligation to make lease payments arising from the lease. Operating lease ROU assets and liabilities are recognized at commencement date based on the present value of lease payments over the lease term. As the Organization's lease does not provide an implicit rate, the Organization uses a risk-free rate based on U.S Treasury note or bond rates for a similar term available at commencement date in determining the present value of lease payments. The operating lease ROU asset also includes any lease payments made and excludes lease incentives. The lease term includes an option to extend or terminate the lease when it is reasonably certain that the Organization will exercise that option. Lease expenses for lease payments are recognized on a straight-line basis over the lease term. The lease agreement does not contain any material residual value guarantees or material restrictive covenants.

Right-of-use assets are assessed for impairment in accordance with the Organization's long-lived asset policy. The Organization reassesses lease classification and remeasures right-of-use assets and lease liabilities when a lease is modified, and that modification is not accounted for as a separate new lease or upon certain other events that require reassessment in accordance with Topic 842.

The Company made significant assumptions and judgments in applying the requirements of Topic 842. In particular, the Company:

**FOUNDATION FOR ANGELMAN SYNDROME THERAPEUTICS, TRANSFORMATX
BIOTHERAPEUTICS LLC, MAVRIX BIO LLC, and AS2 BIO INC
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
FOR THE YEARS ENDED DECEMBER 31, 2024 AND 2023**

2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Continued)

- a) Evaluated whether a contract contains a lease, by considering factors such as whether the Company obtained substantially all rights to control an identifiable underlying asset and whether the lessor has substantive substitution rights;
- b) Determined whether contracts contain embedded leases;
- c) Determined for leases that contain a residual value guarantee, whether a payment at the end of the lease term was probable and, accordingly, whether to consider the amount of a residual value guarantee in future lease payments; and
- d) Allocated consideration in the contract between lease and nonlease components

3. PRIOR PERIOD ADJUSTMENT

FAST recorded two prior period adjustments for the year ended December 31, 2023. The first adjustment was to correct an estimate on uncollectible pledges to account for the potential uncollectability of a long-term pledge made in previous years. The change in estimate reflected an adjustment to net assets with donor restrictions and allowance for uncollectible pledges in the amount of \$2,000,000.

The second adjustment was to account for a grant that was pledged by FAST in 2023, in 2024, before the grant obligations were fully met, was transferred to a related party to continue the work under a service agreement. Therefore, the adjustment is to reflect the write-down of that pledge in the year made as a change in estimate. The change reflects an adjustment in long-term liabilities and net assets with donor restrictions in the amount of \$6,031,508.

The total amount of these adjustments collectively were \$4,031,508.

The adjustments had the following impact on the 2023 consolidated financial statements:

Total assets as originally stated	\$ 57,215,410
Total assets as restated	<u>55,215,410</u>
Adjustment to total assets	<u>\$ (2,000,000)</u>
 Total liabilities as originally stated	 \$ 19,238,043
Total liabilities as restated	<u>13,206,535</u>
Adjustment to total liabilities	<u>\$ 6,031,508</u>
 Total net assets with donor restrictions as originally stated	 \$ 39,805,401
Total net assets with donor restrictions as restated	<u>43,836,909</u>
Adjustment to total net assets with donor restrictions	<u>\$ 4,031,508</u>

**FOUNDATION FOR ANGELMAN SYNDROME THERAPEUTICS, TRANSFORMATX
BIOTHERAPEUTICS LLC, MAVRIX BIO LLC, and AS2 BIO INC
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
FOR THE YEARS ENDED DECEMBER 31, 2024 AND 2023**

4. LIQUIDITY AND AVAILABILITY OF RESOURCES

The following represents FAST's financial assets at December 31, 2024 and 2023:

	<u>2024</u>	<u>2023</u>
Financial assets at year-end:		
Cash and cash equivalents	\$ 1,155,343	\$48,223,283
Contributions receivable	415,000	219,320
Accounts receivable	619,294	-
Investments, at fair value	24,642,403	591
Investments at net asset value (NAV)	<u>6,281,350</u>	<u>5,674,102</u>
 Total Financial Assets	 33,113,390	 54,117,296
 Less amounts not available to be used within one year		
Board approved grants payable	1,868,208	9,029,559
Net assets with donor restrictions	<u>15,457</u>	<u>15,457</u>
	<u>1,883,665</u>	<u>9,045,016</u>
 Financial assets available to meet general expenditures over the next twelve months	 <u>\$ 31,229,725</u>	 <u>\$45,072,280</u>

FAST's goal is to maintain financial assets to meet 90 days of operating expenses (approximately \$4 million). FAST annually seeks to issue grants for research funding of approximately \$1 million and invest \$10-\$15 million in the AS pipeline.. As part of its liquidity plan, excess cash is invested in money market accounts, mutual funds, and program-related investments.

5. INVESTMENTS AT FAIR VALUE AND NET ASSET VALUE

For the years ended December 31, 2024 and 2023, respectively, FAST's investment portfolio consists of common stock and an investment in a hedge fund. The hedge fund as an alternative investment is considered a Level 2 asset and is measured at net asset value (NAV) per share. Total shares in this investment were 2,730.6149 with a NAV per share of 2,300.343 totaling \$6,281,350. The redemption timing is semi-annually with ninety-five days notice. The fair market value of investments is below.

The following table summarizes the investments as of December 31, 2024:

<u>Level 1 - FMV</u>	<u>Level 2</u>	<u>Level 3</u>	<u>Total</u>
\$24,642,403	\$ 6,281,350	\$ -	\$ 30,923,753

The following table summarizes the investments as of December 31, 2023:

<u>Level 1 - FMV</u>	<u>Level 2</u>	<u>Level 3</u>	<u>Total</u>
\$ 591	\$ 5,674,102	\$ -	\$ 5,674,693

**FOUNDATION FOR ANGELMAN SYNDROME THERAPEUTICS, TRANSFORMATX
BIOTHERAPEUTICS LLC, MAVRIX BIO LLC, and AS2 BIO INC
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
FOR THE YEARS ENDED DECEMBER 31, 2024 AND 2023**

6. INVESTMENTS USING THE EQUITY METHOD

In 2022, FAST sold all of their membership interests in GeneTx to an unrelated third party. As a result of the sale, FAST received approximately \$52 million for their member interests in GeneTx. FAST expects to receive continued royalties as part of the purchase agreement based on certain financial metrics. Royalties received for the year ended December 31, 2023 totaled \$1,113,223 and are recorded when received since they are contingent on certain metrics. There were no royalties received in 2024.

In 2024, FAST invested \$1,000,000 in Couragene, Inc. for 3.846% of stock ownership in the Company in the form of preferred stock shares. FAST does not exert control over this entity and has one board seat; thus, treats the investment on the cost method. FAST does not believe there is an impairment on their investment in 2024.

Also, in 2024, FAST invested \$5,000,081 in CourageAS (a joint venture) for 23.94% of preferred stock and 14.36% of common stock of that entity. Since FAST exerts significant control over CourageAS through board representation, voting rights, as well as material transactions due to their investment, FAST has elected to use the equity method to value the investment. Under the equity method, the investment is initially recorded at cost then reduced by dividends and increased or decreased by FAST's proportionate share of the investee's net earnings or loss. There were no net earnings or losses nor dividends received in 2024.

7. RELATED PARTIES

Board members

Board members provided contributions totaling \$339,321 for the year ended December 31, 2024. None of these contributions remain outstanding or were reported as contributions receivable as of December 31, 2024.

Board members provided contributions totaling \$701,000 for the year ended December 31, 2023.

8. NET ASSETS

Net assets with donor restrictions for December 31, 2024 and 2023 totaled \$15,457 to be used for clinical trial travel.

No net assets with donor restrictions were released from restrictions during 2024 or 2023.

**FOUNDATION FOR ANGELMAN SYNDROME THERAPEUTICS, TRANSFORMATX
BIOTHERAPEUTICS LLC, MAVRIX BIO LLC, and AS2 BIO INC
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
FOR THE YEARS ENDED DECEMBER 31, 2024 AND 2023**

9. GRANTS AND GRANTS PAYABLE

In 2019, FAST pledged a grant of \$1,111,112 for translation research in a pig model of Angelman Syndrome to Texas A&M University. None of this pledge was paid out as of the end of 2019. \$546,929 was paid out by the end of 2020. This remaining amount of this grant was to be paid out over a two-year period; therefore, this pledge was discounted accordingly to the present value amount using the U.S. Treasury long term adjusted rate at the time the pledge was authorized (1.59%) plus a risk-free rate of .5% totaling 2.09%. For the year ended December 31, 2023, the amount remaining to be paid was \$37,546. The grant was paid in full in 2024.

In 2022, FAST pledged a grant of \$4,870,000 to establish a new center at Rush University Medical Center that will be known as the RUSH F.A.S.T Center for Translational Research and to fund research done at this new development center. The grant calls for varying installment payments over a ten-year period. This pledge was discounted accordingly to the present value amount using the U.S. Treasury long term adjusted rate at the time the pledge was authorized (4.34%). No risk-free rate was used. For the years ended December 31, 2024 and 2023, the amount remaining to be paid was \$3,261,900 and \$3,582,400, respectively. The amount remaining to be discounted over the life of the grant is \$895,058.

In 2023, FAST pledged a grant of \$9,651,081 to the University of Pennsylvania for research to support preclinical development of AS Gene Therapy Products. \$1,853,254 was paid in 2023. The grant calls for varying installment payments over a five-year period. This pledge was discounted accordingly to the present value amount using the U.S. Treasury long term adjusted rate at the time the pledge was authorized (3.720%). No risk-free rate was used. As part of this grant, contingent milestone payments for development and sales of products related to this research may be paid once met.

As part of this grant, FAST contracted with the Center for Breakthrough Medicine for \$2,337,500 plus \$2,500,000 in pass through cost totaling \$4,837,500 along with estimated management and legal costs of \$1,033,919 totaling \$5,870,919. This was scheduled to be paid in 2024 and 2025.

For the year ending December 31, 2023, the amount remaining to be paid was \$13,112,345. The amount to be discounted over the life of the grant is \$398,088.

In 2024, this grant was transferred to MavriX in the form of a services agreement and was no longer a grant owed by FAST. After payments were made in 2024, the amount of the remaining grant at the time of the transfer was \$6,318,270. Since this was a material change in estimate, a prior period adjustment was made in 2023 to write off the remaining unpaid grant at the time of transfer. As such, there is no balance owed on this grant as of December 31, 2024.

**FOUNDATION FOR ANGELMAN SYNDROME THERAPEUTICS, TRANSFORMATX
BIOTHERAPEUTICS LLC, MAVRIX BIO LLC, and AS2 BIO INC
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
FOR THE YEARS ENDED DECEMBER 31, 2024 AND 2023**

9. GRANTS AND GRANTS PAYABLE (Continued)

FAST has numerous other grants pledged to other universities for research related to Angelman Syndrome that are payable in 2025. These total \$1,868,288 as of December 31, 2024.

	<u>2024</u>	<u>2023</u>
Total grants payable	\$ 4,827,908	\$ 19,802,523
Less: Discount rate to present value	<u>895,058</u>	<u>1,586,870</u>
	3,932,850	18,215,653
Less: Grants payable within one year, net of discount rate	<u>1,710,787</u>	<u>8,753,898</u>
Net Long-Term Grants Payable	<u><u>\$ 2,222,063</u></u>	<u><u>\$ 9,461,755</u></u>

Aggregate maturities of grants payable are as follows:

Year ending December 31:	
2025	\$ 1,868,288
2026	282,700
2027	240,000
2028	1,291,600
2029	<u>1,145,400</u>
	4,827,988
Less: discount rate to present value	<u>(895,058)</u>
Total	<u><u>\$ 3,932,930</u></u>

10. CONCENTRATIONS

During the year ended December 31, 2024, one individual accounted for 11% of the total general contributions provided to FAST. Two donors made up the entire amount of contributions receivable as of December 31, 2024.

During the year ended December 31, 2023, contributions receivable from one donor totaled 86% of the total contributions receivable as of December 31, 2023.

**FOUNDATION FOR ANGELMAN SYNDROME THERAPEUTICS, TRANSFORMATX
BIO THERAPEUTICS LLC, MAVRIX BIO LLC, and AS2 BIO INC
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
FOR THE YEARS ENDED DECEMBER 31, 2024 AND 2023**

11. OPERATING LEASES

FAST has a software services agreement with a third party to utilize software over a 5-year period which qualifies as a right-of-use asset and is classified as an operating lease through February 2027. The agreement provides an annual payment of \$22,900 for annual fees and usage.

FAST's services agreement has lease and non-lease components which are accounted for as a single lease component. For arrangements accounted for as single lease components, there may be variability in future lease payments as the amount of the non-lease component is typically revised from one period to the next. These are recognized on the statement of functional expenses in the period in which the obligation for those payments is incurred.

The operating lease right-of-use assets and operating leases liabilities as of December 31, 2024 are presented on their own lines on the statement of financial position. FAST does not have any finance leases. During the year ended December 31, 2024, lease expense of \$21,105 was incurred.

The right-of-use assets and lease liabilities were calculated using a weighted average discount rate of 3.84%. As of December 31, 2024, the weighted average remaining lease term was 2 years.

Future minimum lease payments under non-cancellable operating leases as of December 31, 2024 were as follows:

Year ending December 31:	
2025	22,900
2026	<u>22,900</u>
Total lease payments	45,800
Less: present value discount	<u>(1,074)</u>
Total lease liabilities	44,726
Less: current portion	<u>22,801</u>
Long-term lease liabilities	<u><u>\$ 21,925</u></u>

**FOUNDATION FOR ANGELMAN SYNDROME THERAPEUTICS, TRANSFORMATX
BIOTHERAPEUTICS LLC, MAVRIX BIO LLC, and AS2 BIO INC
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
FOR THE YEARS ENDED DECEMBER 31, 2024 AND 2023**

11. OPERATING LEASES (Continued)

The following includes supplement cash flow information related to operating leases for the year ended December 31, 2024:

Cash paid for amounts included in the measurement of lease liabilities:

Net operating cash flows from operating leases \$21,105.

12. RETIREMENT PLAN

FAST implemented a 401(k)-retirement plan in September 2022. Employees are eligible to participate in the plan upon hiring. The plan has an automatic deferral percentage of 3% that increases each plan year by 1% not to exceed 6%. Employees can elect to opt-out or revise deferral percentages at any time. FAST will match 100% of the employees' deferrals up to the first six percent of plan compensation. Total employer match paid for years ended December 31, 2024 and 2023 was \$69,859 and \$40,922, respectively.

13. SUBSEQUENT EVENTS

FAST evaluated subsequent events through September 24, 2025; the date these financial statements were available to be issued. Management has determined that no events or transactions have occurred subsequent to the statement of financial position date that require additional disclosure in the financial statements.